Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging therapies in osteoporosis.

B R MacDonald1, M Gowen

  • 1Musculoskeletal Clinical Research, North American Medical Affairs, GlaxoSmithKline Pharmaceuticals, 1250 S. Collegeville Road, Collegeville, PA, 19426-0989, USA. Brian_R_MacDonald@sbphrd.com

Best Practice & Research. Clinical Rheumatology
|August 4, 2001
PubMed
Summary

Alendronate revolutionized osteoporosis treatment in 1994. Current research focuses on developing new, well-tolerated therapies with enhanced efficacy to address unmet medical needs in bone loss management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.

Bone·2006
Same author

Inhibition of cathepsin K--a novel approach to antiresorptive therapy.

Expert opinion on investigational drugs·2005
Same author

A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.

Bone·2002
Same author

Clusterin expression in adult human normal and osteoarthritic articular cartilage.

Osteoarthritis and cartilage·2002
Same author

Identification and initial characterization of 5000 expressed sequenced tags (ESTs) each from adult human normal and osteoarthritic cartilage cDNA libraries.

Osteoarthritis and cartilage·2001
Same author

Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2001

Area of Science:

  • Pharmacology
  • Bone Biology
  • Clinical Therapeutics

Background:

  • Osteoporosis treatment significantly advanced with alendronate's 1994 approval, offering the first therapy with proven efficacy.
  • Since alendronate, multiple anti-resorptive agents have been approved, expanding treatment options and indications, including male and glucocorticoid-induced osteoporosis.

Purpose of the Study:

  • To review the evolution of osteoporosis treatment since alendronate's introduction.
  • To identify current unmet medical needs in osteoporosis management.
  • To discuss ongoing research and development of novel therapeutic agents.

Main Methods:

  • Review of historical data and clinical approvals for osteoporosis medications.
  • Analysis of current therapeutic landscape and unmet needs.

Related Experiment Videos

  • Discussion of emerging drug targets and development challenges.

    • Main Results:

    • Alendronate and subsequent anti-resorptives have transformed osteoporosis care.
    • Significant unmet needs persist regarding therapy tolerability, convenience, and superior efficacy.
    • Novel anti-resorptive and anabolic agents are under development, targeting improved long-term patient benefit.

    Conclusions:

    • Despite progress, osteoporosis treatment requires further innovation to meet patient needs.
    • Development of new therapies faces challenges in safety, efficacy, and clinical trial design.
    • Future research focuses on advanced anti-resorptive and anabolic strategies for superior osteoporosis management.